Literature DB >> 16234358

Prognostic value of HIV-1 Gag-specific CD4+ T-cell responses for progression to AIDS analyzed in a prospective cohort study.

Christine A Jansen1, Iris M De Cuyper, Berend Hooibrink, Akke K van der Bij, Debbie van Baarle, Frank Miedema.   

Abstract

The causal relationship between HIV-specific CD4+ T-cell responses and viral control and the effect of these responses on the natural history of HIV infection is unclear. In a detailed longitudinal study, functional HIV-1 Gag-specific CD4+ T cells were analyzed in long-term asymptomatic individuals (LTA; n = 6) and progressors to AIDS (n = 7) with a median follow-up of, respectively, 118 and 57 months. Next, HIV-specific CD4+ T-helper cell responses were measured in a prospective cohort study among 96 HIV seroconverters and were related to clinical endpoints using Cox proportional hazard analyses. In the detailed study, no difference for HIV-specific helper-cell responses between LTAs and progressors was observed early in infection, but Gag-specific CD4+ T cells producing IL-2 or IFNgamma were lost in progressors late in infection. Multivariate proportional hazard analyses in the prospective cohort study showed that HIV-specific IL-2+, IFNgamma+, or IL-2+IFNgamma+ CD4+ T cells early after seroconversion had no prognostic value for the rate of progression to AIDS. Our results are compatible with viral load determining the nature and magnitude of HIV-specific CD4+ T-cell responses, rather than HIV-specific CD4+ T-cell responses controlling HIV plasma viral load.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16234358     DOI: 10.1182/blood-2005-07-2907

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease.

Authors:  Shailesh K Choudhary; Nienke Vrisekoop; Christine A Jansen; Sigrid A Otto; Hanneke Schuitemaker; Frank Miedema; David Camerini
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

2.  Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.

Authors:  Lucy Dorrell; Hongbing Yang; Beatrice Ondondo; Tao Dong; Kati di Gleria; Annie Suttill; Christopher Conlon; Denise Brown; Patricia Williams; Paul Bowness; Nilu Goonetilleke; Tim Rostron; Sarah Rowland-Jones; Tomás Hanke; Andrew McMichael
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  Microfluidic cell concentrator with a reduced-deviation-flow herringbone structure.

Authors:  Ji-Chul Hyun; Jongchan Choi; Yu-Gyung Jung; Sung Yang
Journal:  Biomicrofluidics       Date:  2017-09-27       Impact factor: 2.800

4.  Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort.

Authors:  Frank J M van Kuppeveld; Arjan S de Jong; Kjerstin H Lanke; Gerald W Verhaegh; Willem J G Melchers; Caroline M A Swanink; Gijs Bleijenberg; Mihai G Netea; Jochem M D Galama; Jos W M van der Meer
Journal:  BMJ       Date:  2010-02-25

5.  HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice.

Authors:  Sirika Pillay; Enid G Shephard; Ann E Meyers; Anna-Lise Williamson; Edward P Rybicki
Journal:  J Immune Based Ther Vaccines       Date:  2010-11-19

6.  Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study.

Authors:  Simon J Potter; Christine Lacabaratz; Olivier Lambotte; Santiago Perez-Patrigeon; Benoît Vingert; Martine Sinet; Jean-Hervé Colle; Alejandra Urrutia; Daniel Scott-Algara; Faroudy Boufassa; Jean-François Delfraissy; Jacques Thèze; Alain Venet; Lisa A Chakrabarti
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

7.  Association of HIV-specific and total CD8+ T memory phenotypes in subtype C HIV-1 infection with viral set point.

Authors:  Wendy A Burgers; Catherine Riou; Mandla Mlotshwa; Pholo Maenetje; Debra de Assis Rosa; Jason Brenchley; Koleka Mlisana; Daniel C Douek; Richard Koup; Mario Roederer; Guy de Bruyn; Salim Abdool Karim; Carolyn Williamson; Clive M Gray
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

8.  Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals.

Authors:  Julianna Lisziewicz; Nyasha Bakare; Sandra A Calarota; Dénes Bánhegyi; János Szlávik; Eszter Ujhelyi; Enikő R Tőke; Levente Molnár; Zsolt Lisziewicz; Brigitte Autran; Franco Lori
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

9.  IL-2 production correlates with effector cell differentiation in HIV-specific CD8+ T cells.

Authors:  Laurel E Nomura; Brinda Emu; Rebecca Hoh; Perry Haaland; Steven G Deeks; Jeffrey N Martin; Joseph M McCune; Douglas F Nixon; Holden T Maecker
Journal:  AIDS Res Ther       Date:  2006-07-21       Impact factor: 2.250

10.  Abundance of early functional HIV-specific CD8+ T cells does not predict AIDS-free survival time.

Authors:  Ingrid M M Schellens; José A M Borghans; Christine A Jansen; Iris M De Cuyper; Ronald B Geskus; Debbie van Baarle; Frank Miedema
Journal:  PLoS One       Date:  2008-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.